TUSTIN, Calif., May 8 /PRNewswire-FirstCall/ — AMDL Inc., a US-based pharmaceutical company with major operations in China,announced today its JJB wholly foreign-owned subsidiary located in Shangrao,Jiangxi Province, China has received approval from the Chinese State Food andDrug Administration (SFDA) to re-initiate product production on its smallinjectable manufacturing line which is specifically used to produce theGoodnak(R) anti-aging injectable product and other small volume parenteralsolutions. The SFDA requires all China-based companies engaged in the manufacture ofpharmaceutical products to have “Good Manufacturing Practices” (GMP)certification. In Q108, JJB’s GMP certification expired and the Companyinitiated $1.5 million in plant renovations to bring the facility and itsoperations into compliance with the SFDA. With today’s announcement, JJB hasreopened the Jiangxi-based plant and resumed operations for its smallinjectable manufacturing line. According to Mr. Douglas MacLellan, Chairman and CEO of AMDL, “Based onthe pending renewal of our GMP-certification for the JJB plant we anticipateda temporary cease in operations at JJB and planned accordingly by successfullyamounting adequate product supply to meet distributor demand through SFDAapproval. The manufacturing lines at this facility have resumed operationsand we remain on track with our quarterly and fiscal year business andfinancial projections.”
